Latest / Dr RR Baliga's "Got Knowledge Doc" Podkast

🛡️ One Risk Factor in Atrial Fibrillation: Is It Time for a DOAC?
đź«€ AF + just one stroke-risk factor: anticoagulate or not?
The SINGLE-AF randomized trial tackled this common clinical gray zone. At 24 months, the composite of stroke, systemic embolism, major bleeding, or cardiovascular death occurred in 0.5% with a DOAC vs 1.5% without anticoagulation (HR 0.31; P=0.03). 🎯
⚠️ Only 17 primary events occurred, so the effect estimate remains imprecise.
Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk.pdf
💡 Takeaway: SINGLE-AF strengthens the case for DOAC therapy in selected intermediate-risk AF patients—but individualized decision-making…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.